Presentation is loading. Please wait.

Presentation is loading. Please wait.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

Published byBernice Stokes Modified over 5 years ago

Similar presentations

Presentation on theme: "EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona."— Presentation transcript:

1 EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis Ravetti, MD  Journal of Thoracic Oncology  Volume 11, Issue 6, Pages e78-e80 (June 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Malignant pleural mesothelioma with high epidermal growth factor receptor gene (EGFR) and MNNG HOS Transforming gene (MET) polysomy and disomic control mesothelioma. (A–E) A representative epithelioid mesothelioma showing high EGFR gene polysomy with associated high expression of EGFR protein (A and B, respectively) and high MET gene polysomy with associated moderate expression of epithelial transition factor protein (MET) (C and D, respectively). (F–J) A representative epithelioid mesothelioma showing disomic EGFR and MET (F and H, respectively) and negative expression of EGFR and MET protein (G and I, respectively). EGFR was investigated by fluorescence in situ hybridization (FISH) using Vysis LSI EGFR Spectrum Orange/CEP7 Spectrum Green. MET was investigated by FISH using MET/CEP7 probe cocktail (Vysis MET Spectrum Red FISH Probe Kit reagent/Vysis CEP7 [D7Z1] and Spectrum Green Probe) (all reagents from Abbott Molecular, Des Plaines, IL). A cell with an abnormal copy number of EGFR or MET contains multiple orange or red signals and green signals (CEP7). A cell with a normal copy number of EGFR or MET contains only two orange or red signals and two green signals. White arrows indicate spots of EGFR red signal points and MET orange signal points. Immunohistochemical staining of EGFR was performed with an EGFR pharmDx Kit (DAKO, Milan, Italy), and immunohistochemical staining of MET was performed with Anti-c-Met Antibody IHC-plus LS-B2812 (LSBio, Seattle, WA). Black arrows indicate membrane- and cytoplasmic-positive staining. A, C, F, and H: FISH (magnification, ×100). B, D, G, and I: immunohistochemical staining (magnification, ×40). E and J: hematoxylin and eosin staining (magnification, ×10). Journal of Thoracic Oncology  , e78-e80DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona."

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.

Fig. 1. EGFR content as determined by fluorescence in situ hybridization (FISH) and immunohistochemical staining. FISH was performed with the EGFR ( red.
Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Naomi Fujioka, MD, Christopher A. French, MD, Michael J
Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer?  Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Establishment and Expression Profiling of New Lung Cancer Cell Lines from Chinese Smokers and Lifetime Never-Smokers  David C.L. Lam, MBBS, Luc Girard,

Establishment and Expression Profiling of New Lung Cancer Cell Lines from Chinese Smokers and Lifetime Never-Smokers  David C.L. Lam, MBBS, Luc Girard,
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.
The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in Urine  Irina A. Sokolova,

The Development of a Multitarget, Multicolor Fluorescence in Situ Hybridization Assay for the Detection of Urothelial Carcinoma in Urine  Irina A. Sokolova,
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer  Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer  Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,
Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L

Bob T. Li, M. B. B. S. , MPH, Dara S. Ross, MD, Dara L
Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity.

Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity.

Similar presentations

Ads by Google